Physician profile
Samya Mohammad
NPI 1851683577
$1,911.83
in general payments reported to CMS, 2019-2025
24 companies · $621 in 2025
The $621 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $18.27 · 2022: $102 · 2023: $154 · 2024: $347 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.79 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $263.09 | 2022-2025 | Krystexxa, Otezla |
| Abbvie INC. | $228.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $193.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $191.91 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $168.26 | 2025 | Acthar |
| Pfizer INC. | $166.69 | 2019-2023 | |
| Janssen Biotech, INC. | $115.60 | 2022-2025 | Tremfya |
| Horizon Therapeutics Plc | $109.42 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $61.96 | 2023-2025 | Saphnelo |
| Merck Sharp & Dohme LLC | $54.79 | 2019 | |
| Ucb, INC. | $54.32 | 2024-2025 | Cimzia, Bimzelx |
| Mallinckrodt Enterprises LLC | $53.76 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $36.35 | 2023-2024 | Zilretta, Iovera |
| Fresenius Kabi USA, LLC | $33.37 | 2025 | |
| Saluda Medical Americas, INC. | $23.75 | 2025 | Evoke |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $21.62 | 2019 | |
| Scilex Pharmaceuticals INC. | $21.11 | 2024 | |
| Ardelyx, INC. | $20.74 | 2023 | Ibsrela |
| Lilly USA, LLC | $18.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.96 | 2024 | Orencia |
| Ani Pharmaceuticals, INC. | $16.96 | 2025 | Purified Cortrophin Gel |
| Sobi, INC | $15.43 | 2019 | |
| Pacira Therapeutics, INC. | $13.05 | 2019 | |
| Fidia Pharma USA INC. | $12.77 | 2023 | Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samya Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.